Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for

Company Overview - Pfizer is expected to report quarterly earnings of $0.67 per share, reflecting a year-over-year decline of 18.3% [3] - Revenues are anticipated to be $13.88 billion, down 6.7% from the same quarter last year [3] - The Most Accurate Estimate for Pfizer is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -7.23% [10] Earnings Expectations - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from analysts [4] - A positive or negative Earnings ESP reading indicates the likely deviation of actual earnings from the consensus estimate, with positive readings being more predictive of earnings beats [7][8] - Despite a Zacks Rank of 2 (Buy), the negative Earnings ESP makes it challenging to predict an earnings beat for Pfizer [11] Historical Performance - In the last reported quarter, Pfizer exceeded expectations by delivering earnings of $0.63 per share against an expected $0.48, resulting in a surprise of +31.25% [12] - Over the past four quarters, Pfizer has consistently beaten consensus EPS estimates [13] Industry Context - AbbVie, a peer in the Large Cap Pharmaceuticals industry, is expected to post earnings of $2.40 per share, indicating a year-over-year increase of 3.9% [17] - AbbVie's revenue is projected to be $12.91 billion, up 4.8% from the previous year [17] - AbbVie has an Earnings ESP of -0.92% and a Zacks Rank of 3 (Hold), making it difficult to predict an earnings beat [18]